{"prompt": "['Tofacitinib', 'A3921284 NON-INTERVENTIONAL STUDY PROTOCOL', 'Amended, 12-December-2018', 'NON-INTERVENTIONAL (NI) STUDY PROTOCOL', 'Study information', 'Title', 'Patient-Reported outcomes in rheumatoid', 'arthritis patients treated with tofacitinib or', 'biological disease-modifying antirheumatic', 'drugs (DMARDs) in real life conditions', 'Protocol number', 'A3921284', 'Protocol version identifier', '2.1', 'Date of last version of protocol', '12 December 2018', 'Active substance', 'L04AA29 Tofacitinib', 'Medicinal product', 'XELJANZ', 'Sponsor', 'Pfizer Inc.', 'Research question and objectives', 'This study is aimed to describe the outcomes', 'related to physical activity, activity of', 'disease, quality of life, work productivity', 'CONFIC', 'and safety in Latin-American patients with', 'Rheumatoid Arthritis (RA) treated with', 'tofacitinib or biological DMARDs after', 'failure to respond to conventional DMARDs', 'in real-life conditions', 'Author', 'PPD', 'HE&OR Coordinator', 'Colombia', 'PPD', 'Page 1 of 64']['Tofacitinib', 'A3921284 NON-INTERVENTIONAL STUDY PROTOCOL', 'Amended, 12-December-2018', 'TABLE OF CONTENTS', '1.', 'DISCLOSURE STATEMENT', '5', '2.', 'SPONSOR SIGNATURE', '6', '3.', 'INVESTIGATOR SIGNATURE', '7', '4.', 'LIST OF ABBREVIATIONS', '8', '5.', 'RESPONSIBLE PARTIES', '10', '5.1', 'CONTACTS', '10', '6.', 'FLOWCHART', '12', '7.', 'ABSTRACT', '13', '8.', 'AMENDMENTS AND UPDATES', '16', '9.', 'MILESTONES', '17', '10. RATIONALE AND BACKGROUND', '18', '11. RESEARCH QUESTION AND OBJECTIVES', '21', '11.1', 'Primary objective', '21', '11.2', 'Secondary objectives', '12. RESEARCH METHODS', 'Study design', 'INFIDENTIA', '21', '22', '12.1', '23', '12.2', 'Setting', '23', '12.2.1', 'Inclusion criteria', '23', '12.2.2', 'Exclusion criteria', '24', '12.2.3', 'Sampling process', '24', '12.3 Variables', '25', '12.3.1', 'Variables measured at the initial phase', '25', '12.3.2', 'Effectiveness variables', '27', '12.3.3', 'Safety variables', '28', '12.4', 'Data sources', '29', '12.5', 'Study size', '30', '12.6', 'Data management', '31', '12.6.1', 'Patients selection', '31', '12.6.2', 'Collection of information at the initial phase', '31', '12.6.3', 'Patients follow-up', '32', '12.6.4', 'Case report form', '32', 'Page 2 of 64']['Tofacitinib', 'A3921284 NON-INTERVENTIONAL STUDY PROTOCOL', 'Amended, 12-December-2018', '12.6.5', 'Records retention', '33', '12.6.6', 'Endpoint and covariates', '33', '12.6.6.1', 'Effectiveness endpoint', '33', '12.6.6.2', 'Safety endpoint', '34', '12.6.6.3', 'Covariates', '34', '12.7', 'Data analysis', '35', '12.7.1', 'Working hypothesis', '35', '12.7.2', 'Propensity score', '35', '12.7.3', 'Analysis of effectiveness', '36', '12.7.4', 'Analysis of safety', '36', '12.7.4.1', 'Safety outcomes report monitoring team', '37', '12.7.4.2', 'Missing data management', '37', '12.8', 'Quality control', '37', '12.9', 'Limitations of the research methods', '38', '12.10', 'Other aspects', '38', '13. PROTECTION OF HUMAN SUBJECTS', '39', '13.1', 'Patient information and Consent', '39', '13.2', 'Patient withdrawal', '39', '13.3 Institutional Review Board (IRB)/Independent Ethics Committee (IEC)', '40', '13.4', 'Ethical conduct of the study', '40', '14. MANAGEMENT AND REPORTING OF ADVERSE EVENTS/ADVERSE', 'REACTIONS', '41', '14.1 Secondary Data Collection Study - Includes Protocol-Required Human Review of', 'Unstructured Data', '41', '14.2', 'Other Primary Data Collection Study', '42', '14.3', 'Single reference safety document', '43', '15. PLANS FOR DISSEMINATING AND COMMUNICATING STUDY RESULTS', '43', '16. REFERENCES', '45', '17. LIST OF TABLES', '47', 'ANNEX 1. LIST OF STAND ALONE DOCUMENTS', '48', 'ANNEX 2. HAQ-DI (English version)', '49', 'ANNEX 3. EQ-5D-3L (English version)', '50', 'ANNEX 4. WPAI (English version)', '53', 'Page 3 of 64']\n\n###\n\n", "completion": "END"}